Status:
COMPLETED
Influence of Cannabidiol on Glucose Tolerance and The Gut Microbiota
Lead Sponsor:
Christopher Bell
Collaborating Sponsors:
Caliper Foods
Conditions:
Diabetes
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
While many empirical projects have described multiple potential health benefits of CBD, the potential for CBD to provide protection against the development of diabetes via favorable modification of th...
Detailed Description
More than 122 million Americans have diabetes, or its precursor, pre-diabetes. The clinical and public health implications are not trivial as diabetes is the leading cause of blindness and non-traumat...
Eligibility Criteria
Inclusion
- 18 years of age and older
- Weight more than 110 pounds
- Have a Body Mass Index greater than or equal to 25 kilograms/squared meters
- Free of gastrointestinal or metabolic diseases
- Sedentary (less than 150 minutes of moderate-intensity exercise per week during the previous 3 months)
Exclusion
- Less than 18 years of age
- Pregnant or breastfeeding
- Have known food allergies
- Have been diagnosed with any autoimmune disorders or with compromised immune function
- Celiac disease
- Inflammatory bowel diseases
- Gastrointestinal cancers
- Diabetes
- Human Immunodeficiency Virus
- Adverse reaction to ingesting CBD oils, or CBD containing food products
- Taking any of the following medications will be excluded as these may have negative interactions with CBD:
- steroids,
- 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors,
- calcium channel blockers,
- antihistamines,
- human immunodeficiency virus antivirals
- immune modulators,
- benzodiazepines,
- antiarrythmics,
- antibiotics,
- anesthetics,
- antipsychotics,
- antidepressants,
- anti-epileptics,
- beta blockers,
- coumadin (warfarin),
- proton pump inhibitors,
- non-steroidal anti-inflammatory drugs,
- angiotension II blockers,
- oral hypoglycemic agents,
- sulfonylureas.
Key Trial Info
Start Date :
February 9 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 31 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05285449
Start Date
February 9 2022
End Date
May 31 2024
Last Update
July 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Colorado State University, Dept. of Health and Exercise Science
Fort Collins, Colorado, United States, 80523-1582